The cellular toxicology of mitragynine, the dominant alkaloid of the narcotic-like herb, Mitragyna speciosa Korth by Saidin, NA et al.
  
 
The cellular toxicology of mitragynine, the dominant 
alkaloid of the narcotic-like herb, Mitragyna speciosa Korth 
 
 
Journal: Toxicology Research 
Manuscript ID: TX-ART-04-2015-000113.R1 
Article Type: Paper 
Date Submitted by the Author: n/a 
Complete List of Authors: Saidin, Nor; Imperial College London, Computational and Systems Medicine 
Holmes, Elaine; Imperial College London, Computational and Systems 
Medicine 
Takayama, Hiromitsu; Chiba University, Pharmaceutical Sciences 
Gooderham, Nigel; Imperial College London, Biomolecular Medicine 
  
 
 
Toxicology Research
 Dear Editor, 
Thank you for the reviews on our submission.  The reviewers make some very good 
suggestions that we have incorporated into the text and the revised manuscript is 
now much stronger. I shall address the reviewers’ comments on a point by point 
basis. 
Referee 1 
This is a well written paper and the experiments described, though fairly basic, are 
well performed and analysed. The work explores the mechanism of toxicity of 
mitragynine, the active alkaloid constituent of the herb Mitragyna speciosa Korth, 
and suggests a key molecular initiating event (MIE) that triggers the toxicity cascade.  
We thank the reviewer for the supportive words. 
1. The dose level at which toxicity was seen is 75µM that is some 75,000 to 750 
fold higher that that found in fairly high level users of the herb. This needs to 
be included in the abstract.  
We do mention this fact in the discussion along with the problems of extrapolating in 
vitro data to the situation in humans. To put our data in context, we also comment 
upon the human fatalities associated with Kratom consumption. In line with the 
comment and taking into consideration the reviewer’s point 2, we now include new 
statements in the abstract and expand on this in the discussion.  
2. It would be useful though if some data on plasma levels in individuals who 
have shown profound toxicity or died could be used for comparison. There are 
some published papers in particular PMID 25453780 that has data and these 
data should be included in the discussion and references.  
This is a great point. In fact references 9-11 in our manuscript give details of plasma 
levels of mitragynine in human fatalities associated with Kratom use.  The plasma 
mitragynine concentrations in these individuals varied between 0.45 – 1.5 microM, 
which is 50 fold less than the concentrations used in our studies.  We have therefore 
included a review of these reports in our revised discussion. 
3. Shown in both the cytoxicity assays (fig 2B) and clonogenic assays (Fig 2D) 
the lower doses show a marked cell proliferation. This is not commented on 
and some text should be included to deal with this.  
We have amended the text to comment on this. 
4. The authors looked at the mechanism and hypothesised that the key 
molecular event could be interaction with the opiate receptors. This was 
tested using antagonists against these receptors. Naloxone that has activity 
particularly against the µ and ҝ receptors showed activity in reducing the 
toxicity but naltrindole (active against the δ receptor) did not show activity in 
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reducing the cell toxicity. This implied activity that the key MIE could be an 
agonist action on these receptors, and in particular the µ and ҝ receptors for 
which naloxone is active. If this is the case then similar cytoxicity would be 
expected for all other agonists of these receptors that, particularly for the µ 
receptor, include most of the common opiates. One opiate agonist with 
particular activity against the µ, ҝ and δ receptors is etorphine. There is one 
paper in the literature (PMID 9359460) which shows an inhibition of cell 
growth in SK-N-SH cells using thymidine incorporation from 10µM and this 
should be commented on. The authors should review the literature for 
morphine and other µ receptor agonists. 
The reviewer makes an important point and we have reviewed the literature around 
this.  We note that there is clear evidence in the literature of opiate mediated cell 
toxicity, particularly around morphine.  In the revised submission we now reference 
reports of similar observations to ours, regarding naloxone effects on morphine 
toxicity and their speculation on the role of the µ receptor.  Clearly the role of opioid 
receptors in opiate cellular toxicity remains controversial.  
Minor comments 
a. The resolution of figure 1 needs to be improved. This figure has clearly been 
cut and pasted from elsewhere.  
We have redrawn the figure using Chem-Draw. 
b. Figures 2A and 2B require error bars.  
We apologise for this oversight.  The error bars have been added. 
 
Referee: 2 
Comments to the Author 
1. The results from this study offer some understanding on the toxicity of 
compound which is increasingly being abused. 
We thank the reviewer for their supportive words. 
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ABSTRACT 
Mitragyna speciosa Korth (Kratom), a herb of the Rubiaceae family is indigenous to 
southeast Asia.  The plant and its dominant alkaloid mitragynine (MIT) are 
narcotic/analgesic and illicit consumption is widespread in Asia; the toxicological 
consequences of consumption are poorly documented. We determined cytotoxicity of 
MIT on human cell lines and report dose and time-dependent stimulation and 
inhibition of proliferation. Since MIT has powerful opiate-like activity, we focussed on 
human neuronal SH-SY5Y cell line and found the colony forming ability of cells 
treated with MIT showed a dose-dependent trend for reduced survival. Studies using 
metabolically competent MCL-5 cells and chemical inhibitors indicated that CYP 2E1 
and 2A6 were involved in the cytotoxicity. Cytotoxicity was preceded by cell cycle 
arrest mainly at G1 and S phase.  To assess whether arrest was due to DNA 
damage or mutation, we examined genotoxic potential using the L5178 tk+/- mouse 
lymphoma assay and found that MIT was not genotoxic at the tk locus, even at doses 
that were highly cytotoxic. To investigate mechanisms of MIT cytotoxicity, we used 
flow cytometry and annexin V with 7-amino-actinomycin D staining and show 
apoptosis and necrotic activity. Apoptosis was further supported as MIT rapidly 
induced the activity of executioner caspases 3/7. However, cytotoxicity of MIT was 
partially reduced by inclusion of the opioid receptor antagonist naloxone, a µ and δ 
opioid receptor antagonist, suggesting that cytotoxicity depends in part on opioid 
signalling, consistent with the known toxicity of other opiates. Based on consumption 
of 20 leaves/day of Mitragyna speciosa, we estimated daily human exposure to MIT 
to be about 17 mg MIT for regular consumers, potentially giving plasma 
concentrations in of 10-9 to 10-7 M. Importantly, fatalities after kratom consumption 
have been reported to occur in individuals with blood mitragynine concentrations of 
between 0.45-1.0 µM, substantially lower than the threshold of toxicity predicted from 
this in vitro report. Clearly the implications of these findings to humans consuming 
Mitragyna speciosa leaves will require further study, but individuals taking large 
quantities of these opiate-like materials may be at risk, especially those who have a 
high CYP2E1 activity, such as heavy alcohol users. 
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INTRODUCTION 
The use of traditional medicines from natural products, mainly plants, is increasing in 
developing countries.  Although the safety and efficacy of most of the traditional 
medicines used in humans are yet to be thoroughly investigated, people still turn to 
them due to availability and cost.  Mitragyna speciosa Korth, also known as ‘kratom’ , 
is a traditional plant having unique therapeutic constituents; it is found growing in 
Malaysia, Thailand and neighbouring countries. Mitragyna speciosa Korth plant, 
especially its leaves, has long been consumed by local farmers and labourers who 
chew the fresh leaves, smoke the dry leaves or drink as a tea suspension1  or even 
eat it in the form of resin, for stimulant effects.  The plant has unique dual opioid 
properties which exert a stimulant effect at low doses and sedative and analgesic 
effects at the higher doses in humans2, 3. This characteristic of the plant has led to it 
being highly abused by drug addicts4. The chemistry and pharmacology of the leaves 
of this plant, especially the dominant alkaloid, mitragynine (MIT, Figure 1), is known 
to include opioid-like agonistic effects1, 5, 6. MIT was reported to exert antinociceptive 
and anti-tussive effects upon oral, subcutaneous and intraperitoneal administration to 
rodents 7. Recently the MIT congener, 7-hydroxymitragynine was found to have 
potent opioid-like effects both in vitro and in vivo 8. In contrast to this established 
pharmacology, the toxicological consequences of exposure to these compounds are 
poorly documented. Drug addicts using the plant and its extracts report dry mouth, 
emaciated body with an unhealthy complexion (dry skin and dark lips, resembling 
hepatic face), frequent urination, constipation coupled with small and blackish stools, 
loss of appetite and weight loss, central nervous system depression, reduced smooth 
muscle tone and for heavy users, prolonged sleep 2, 3. In Malaysia, the possession of 
any form of the plant by the public is illegal. However, in other parts of the world, 
kratom is currently not scheduled. The availability of kratom over the internet has 
attracted use of the plant as self-treatment in opioid withdrawal and chronic pain4. 
Recently, there have been several reported fatalities associated with consumption of 
Kratom 9-11.  The reason for these deaths is not understood but MIT toxicity is 
implicated. In view of this and the lack of understanding of the toxicity of MIT, we 
have examined the cytotoxicity potential of MIT, the dominant alkaloid of Mitragyna 
speciosa in human cell lines and the mechanisms involved in this toxicity. 
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MATERIALS AND METHODS 
Chemicals. 
Pure mitragynine (>98% purity) was prepared from Mitragyna speciosa as previously 
described 6 and identity confirmed by comparison to an authentic reference sample 
(from the Institute of Medical research, Kuala Lumpur, Malaysia).  Mitragynine 
(>98%) was dissolved in ethanol and filtered through sterile 0.45 µM filter for cell 
culture studies. Metabolic inhibitors diethyldithiocarmate (DED), a CYP 2A6 inhibitor 
and 3-amino-1,2,4-triazole (ATZ), a CYP 2E1 inhibitor were purchased from Sigma-
Aldrich Company (Poole, England). For flow cytometry analysis, Alexa Fluor® 647-
Annexin V conjugate staining kit, 7-Amino-actinomycin D (7-AAD) dye and HEPES 
buffer were obtained from Invitrogen, U.K. The opioid receptor antagonists, naloxone, 
naltrindole and cyprodime hydrobromide were purchased from Sigma-Aldrich, U.K. 
For the caspase studies, the Apo One® Homogenous Caspase 3/7 kit was 
purchased from Promega, U.K. The fluorescent dye, 2,7-dichlorofluorescein 
diacetate (DCFH-DA) and hydrogen peroxide (H202) for ROS assay were purchased 
from Sigma-Aldrich, U.K. 
 
Cell line and conditions. 
The SH-SY5Y and HEK 293 cell lines were purchased from the European Collection 
of Cell Cultures (Salisbury, UK) and the MCL-5 cell line was purchased from Gentest 
Corp. (MA, USA).  The mouse lymphoma L5178Y TK+/- cells were a kind gift from Dr 
M O’Donovan AstraZeneca (Macclesfield, UK). MCL-5 cells, a metabolically 
competent human lymphoblastoid cell line stably transfected with plasmids encoding 
CY1A2, 2A6, 2E1, 3A4, epoxide hydrolase and constitutive 1A1 were cultured in 
RPMI 1640; HEK 293, a human embryo kidney cell line was cultured in high glucose 
Dulbecco’s modified Eagle’s medium (DMEM) and SH-SY5Y cells, a human 
neuroblastoma cell line was cultured  in high glucose Glutamax® DMEM. All media 
were from Invitrogen Corporation (Paisley, Scotland, UK). MEM, DMEM and 
Glutamax® DMEM media were supplemented with 10% fetal bovine serum (FBS), 
2mM L-glutamine and 100 units of penicillin/streptomycin, all from Invitrogen.  RPMI 
1640 was supplemented with 9% horse serum, 2 mM L-glutamine, 2mM histidinol 
and 100 units of penicillin/streptomycin, also from Invitrogen.  Routinely, cells were 
maintained at 37°C, in a humidified atmosphere of 95%/5% air/CO2. Adherent cell 
lines, HEK 293 and SH-SY5Y cells were harvested by trypsinisation with trypsin-
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EDTA (Invitrogen) and centrifugation, and subcultured appropriately; suspension cell 
lines, MCL-5 cells were harvested by centrifugation. Histidinol (2 mM) was added to 
every subculture of MCL-5, for plasmid maintenance. 
 
Cell viability (Trypan blue exclusion assay). 
In order to estimate the percentage of dead cells after treatment with MIT, cells were 
harvested then stained with trypan blue solution (0.4%) and the number of trypan 
blue-positive (dead cells) and trypan blue negative (live) cells were counted with a 
haemocytometer under a light microscope.   
 
In some experiments, the role of opioid receptors in mediating MIT toxicity was 
investigated; three opioid receptor antagonists were used; naloxone (1 µM, µ and δ 
opioid antagonist), naltrindole (1 µM, δ opioid antagonist) and cyprodime 
hydrobromide (1 µM, µ opioid antagonist).  
 
Colony survival (clonogenicity assay). 
For survival studies, cells (SH-SY5Y and HEK 293 cells) treated with MIT, were 
trypsinised, centrifuged and seeded at 100 cells per well in 6 well plates in 2 ml drug-
free medium and incubated for a period of 6-7 days.  The wells were stained with 
methylene blue (1% in 50% methanol) and colonies that contained 50 or more cells 
were scored as survivors. Relative cell survival was expressed as percentage of 
appropriate vehicle-treated controls. In some experiments, the effect of metabolic 
activation on MIT cytotoxicity was also examined using using Arochlor-induced rat 
liver S9 (9 µg protein). 
 
Flow cytometry analysis (cell cycle analysis). 
Treated SH-SY5Y cells were harvested by routine trypsinisation, washed with PBS 
and fixed in ice-cold 70% ethanol overnight. The fixed cells were then collected by 
centrifugation (1200 r.p.m. for 5 min) and re-suspended in staining solution 
containing 5 mg/ml propidium iodide (PI),10 µg/µl RNase and 0.1% triton-x100 and 
incubated at 37ºC for 30 minutes.  Samples were analysed using the Cellquest Pro 
software on a Becton Dickinson FACSCalibur flow cytometer. For each sample, 
30,000 events were collected and aggregated cells were gated out of the analysis.  
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The percentage of cells at different phases of the cell cycle was determined using 
ModFit LT MAC 3.1 software. PI was excited at 488 nm, and the fluorescence 
analysed at 620 nm. 
 
Immunoblot analysis. 
Cell lysates (10 µg protein) were resolved by SDS-polyacrylamide gel electrophoresis 
and electroblotted onto nitrocellulose membrane. Blots were blocked by incubation in 
5% low fat dried milk in 25 mM phosphate buffered saline and 0.1% tween 20 for 45 
minutes at room temperature. The nitrocellulose blot was incubated with primary 
antibody overnight at 4°C, followed by secondary antibody conjugated to horseradish 
peroxidase for 1 hr at room temperature. Detection was achieved using ECL kit 
(Amersham Life Science, UK). The antibodies against p53 (1 in 2000 dilution) were 
purchased from Santa Cruz, (California, USA) and the β-actin antibody (1 in 20,000 
dilution) was purchased from Sigma-Aldrich (Poole, England). The quantitation of 
each immunoblot obtained was carried out using a UMAX powerlook 1100 scanner, 
and the p53 band intensity normalised to β-actin was analysed using Image J version 
1.37 software. 
 
The L5178Y TK+/-  mouse lymphoma cell assay. 
The mouse lymphoma L5178Y TK+/- cells were maintained in RPMI 1640 Glutamax-1 
medium containing 3.0 mM L-glutamine and 25 mM HEPES and supplemented with 
1.8 mM sodium pyruvate, 50 µg/ml streptomycin: 50 IU/ml penicillin, 0.1% pluronic F-
68 and 10%(v/v) heat inactivated  donor horse serum.  The cells were treated prior to 
use in the assay with thymidine (9 µg/ml), hypoxanthine (15 µg/ml), methotrexate (0.3 
µg/ml ) and glycine (22.5 µg/ml ) to maintain a low and stable background mutant 
frequency.  7,12-Dimethylbenz[a]anthracene (DMBA) was used as positive control in 
the presence of aroclor induced rat liver S9-mix at a final concentration of 5 µg/ml, 
dissolved in DMSO.  Methyl methanesulfonate (MMS) dissolved in dimethyl 
sulphoxide was used as a positive control in the absence of S9-mix at final 
concentration of 20 µg/ml.  The assay was performed in a 96 well plate format as 
described by Clements12 and Moore et al., 13.  After treatment with MIT (3h in the 
presence of aroclor induced rat liver S9 or 24 h in the absence of S9), cells were 
harvested.  Treated cells (106) were suspended in normal culture media for 48 h to 
permit expression of the tk-/- phenotype.  An aliquot of cell suspension was then 
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plated out for viability in a 96 well plate at a density of 1.6 cells per well.  For mutant 
selection, trifluorothymidine was added to the cell suspension to give a final 
concentration of 4 mg/ml, cells were added to each well of a 96 well plate at a density 
of 2000 cells per well.  The plates were incubated for 12 days at 37C in a humidified 
atmosphere of 5% CO2.  At the end of this period, wells containing no viable cells 
were identified and counted.  The mutant frequency (MF), plating efficiency and 
relative total growth (RTG) were determined as previously described 12, 13.  
 
Annexin V conjugates/7-AAD double staining for apoptosis detection 
Double staining for cellular DNA using Alexa Fluor® 647-Annexin V conjugate 
staining kit and 7-AAD were performed following manufacturer’s instruction. SH-
SY5Y cells (1 x 106) in exponential growth phase were incubated for 2 hours or 
overnight, and treated with various concentrations of MIT and further incubated at 
37°C (5% CO2) for 24 hour. After harvesting, cell pellets were washed with cold PBS 
followed by centrifugation (1200 r.pm.).  Cells were re-suspended in Annexin-binding 
buffer (10mM HEPES, 150 mM NaCl and 2.5 mM CaCl2  at pH 7.4) and then counted 
and the cell density adjusted to 1 x 106 cells/ml.  Alexa Fluor® 647-Annexin V 
conjugate (5 µl) was added to each 100 µl of assay and incubated at room 
temperature in the dark for 15 min.  The Annexin-binding buffer (200 µl) was added 
to the suspension and kept on ice followed by adding 2 µl/100 µl cells suspension of 
the 7-AAD (1 mg/ml in phosphate buffer). The cells were then incubated on ice for 5 
minutes until data acquisition with a Becton Dickinson FACSCalibur flow cytometer 
using CellQuest Pro software. The fluorescence of AlexaFluor®647- Annexin V 
conjugate  was measured at 650 nm excitation and 665 nm emission and 7-AAD at 
488 nm excitation and 620 nm emission. Thirty thousand (30,000) cells were 
analysed for each treatment using FLOW JO 8.1.1 software. 
 
Apo One® homogenous caspase 3/7 assay 
SH-SY5Y cells (105 cells/ well of six well plates) were treated with MIT for 4 hr or 18 
hr. After incubation, cells were harvested by trypsinisation and centrifugation. The 
assay was performed according to the manufacturer’s instructions (Promega, USA). 
After cell counting, 20,000 cells in 100 µl volume were transferred to 96 well black 
plates. One hundred microliter of caspase 3/7 reagents (mixture of caspase substrate 
and caspase buffer) was added to each well, shaken for 30 seconds and incubated 
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at room temperature. Serial fluorescence readings were performed over at least 1 h 
using a plate reader at 485 nm excitation and 520 nm emission.  
 
Reactive oxygen species (ROS) analysis 
ROS assay was carried out using SH-SY5Y cells and the fluorescent dye 2,7-
dichlorofluorescein diacetate (DCFH-DA).  This dye diffuses through the cell 
membrane and is hydrolysed enzymatically by intracellular esterases to form 
monofluorescent dichlorofluorescein (DCFH) in the presence of ROS. The intensity of 
the fluorescence is proportional to the levels of intracellular ROS 14. Briefly, SH-SY5Y 
cells (2 x 103 cells/well) in 24 well plates were cultured overnight, then the medium 
was aspirated and washed with PBS to remove all traces of albumin (a free-radical 
quencher). PBS (2 ml) was added to each well followed by freshly prepared DCFH-
DA dye dissolved in DMSO (10 µL of100 µM) under subdued lighting. In some 
experiments, anti-oxidant, N-acetyl-L-cysteine (NAC) (5mM) was also added. After 
30 minutes, cells in each well were treated with H202 (positive control) or MIT and the 
fluorescence was measured using a plate reader with 485 nm excitation and 530 nm 
emission. Fluorescence readings were continually read at 10 min intervals for up to 1 
hr period.   
 
Statistical analysis. 
One way Analysis of variance (ANOVA) with Tukey-Kramer or Dunnet post tests was 
conducted to calculate significant differences where p-values of <0.05 were 
considered significant. 
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RESULTS 
Cell viability by trypan blue exclusion assay. 
MIT treated cells showed stimulation and inhibition of cell proliferation that was dose 
and time-dependent in the human cell lines examined (HEK 293, MCL-5 and SH-
SY5Y cells) (Figure 2); SH-SY5Y and MCL-5 cells were more sensitive to the 
treatments (Table 1). At low doses, proliferation was stimulated in the SH-SY5Y cell 
line at the 24 and 48 h time points; this was less pronounced in the HEK293 cell line. 
The reason for the increased proliferative response is not clear and it should be 
noted that there was considerable variability in the data. By 72 h this stimulatory 
effect was no longer apparent. As the dose was increased, toxicity became more 
evident, particularly in the SH-SY5Y cells where survival was negligible at the highest 
dose employed, irrespective of incubation period. The effect of CYP expression on 
MIT proliferation and toxicity (trypan blue uptake) was examined in metabolically 
competent MCL-5 cells. In preliminary experiments, ketoconazole (CYP 3A4 inhibitor 
at 25 µM), diethyldithiocarbamate (DED) (CYP 2A6 inhibitor at 100 µM ), 3-amino-
1,2,4-triazole (ATZ) (CYP 2E1 inhibitor at 25 µM) and α-naphthoflavone (CYP 1A 
inhibitor at 25 µM) were incubated with MCL- 5 cells and MIT. Only DED and ATZ 
were found to alter MIT cytotoxicity (data not shown), therefore, the effect of DED 
and ATZ on MCL-5 proliferation and cytotoxicity was examined in more detail (Fig. 
2C).  Both ATZ and DED reduced toxicity at 50 µM MIT.  At 100 µM MIT, ATZ 
showed some inhibition of toxicity, although this was not statistically significant and 
DED was without effect. 
 
Colony survival (clonogenicity assay). 
The clonogenicity assay is a longer term measure that assesses not only the effects 
of cell death but also the ability of cells to form a colony. As shown in Figure 2D, 
under these conditions, the inhibition of proliferation by MIT is overcome on 
prolonged culture and colony formation although there was a significant trend for 
clonogenic cytotoxicity with increasing dose (p< 0.05 for trend). Interestingly, an 
increased clonogenic response of the SH-SY5Y cells at low dose MIT (0.3uM) was 
observed, although this effect was not statistically significant.  
  
Assessment of cell cycle distribution by flow cytometry. 
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To determine whether MIT treatment could affect the progression of cell cycle, 
treated cells were stained with propidium iodide and analysed by flow cytometry. The 
DNA profiles of SH-SY5Y cells were assessed after exposure to various 
concentrations of MIT (Figure 3). There were no major effects on the cycle seen with 
doses up to 30 µM MIT for 24 hr. However, striking changes were evident at the 
highest dose tested, 75 µM MIT, where cells accumulated at G1 phase and the 
population appeared to shift to increased fluorescence (right shift), consistent with 
treated cells taking up more PI dye (Figure 3).   
 
Mouse lymphoma thymidine kinase (tk-/-) gene mutation assay  
In view of the striking effect on cell cycle at 75 µM, we investigated the ability of MIT 
to damage DNA and induce mutation using the mouse lymphoma tk assay. The 
results are shown in table 2.  For this assay, a positive result is described as a MF 
that is higher than the sum of Mean Control MF (77 x 10-6) plus the standard global 
evaluation factor for this microplate assay (GEF, 126 x 10-6, Moore et al.13).  In the 
presence of S9, there was a slight increase in mutant frequency with the two highest 
doses, but the mutant frequency remained within the GEF and is therefore not 
considered to be a mutagenic response. The positive control DMBA gave a clear 
positive response. There was very little toxicity, assessed as the RTG, noted under 
these conditions. In the absence of S9 during a 24 h incubation, MIT was dose 
dependently cytotoxic.  Cytotoxicity as measured by the RTG was substantial at the 
highest dose. Again, there was a small dose dependent increase in the mutant 
frequency, but still within the GEF and thus the compound was not considered to be 
mutagenic. Again the positive control, MMS, gave a clear positive response.   
 
Immunoblot analysis. 
Since the cytotoxicity of MIT was accompanied by cell cycle arrest, it was proposed 
that these changes could be a result of alteration in the expression and activation of 
regulatory proteins such as p53.  Therefore, the effects of MIT on p53 protein levels 
were assessed in SH-SY5Y cells. Between doses of MIT, there was little difference in 
the expression of p53, however at all concentrations of MIT there appeared to be a 
loss of p53 expression compared to the control group (Figure 4).  
 
Annexin V conjugate assay for apoptosis detection 
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Our preliminary observations on the toxicity of MIT indicated that MIT induced cell 
morphology changes indicative of apoptosis with microscopic evidence of chromatin 
condensation, in SH-SY5Y cells. We therefore explored the mechanisms of MIT-
induced cell death. Translocation of phosphatidylserine to the outer plasma 
membrane indicates early apoptotic cell death, and Annexin V reactivity can be used 
as a marker for apoptotic cells 15, 16.  The cells become reactive with Annexin V prior 
to the loss of the ability of the plasma membrane to exclude the dye 7-AAD and thus 
detection of unaffected (live) cells, early apoptotic, necrotic and late apoptotic cells is 
possible17. 
 
The cell populations were gated according to four different quadrants (Figure 5); Q1 
represent live cells (exclude Annexin V and 7-AAD), Q2 are Annexin V positive 
indicating early apoptosis, Q3 are Annexin V and 7-AAD positive indicating late 
apoptosis/necrosis and Q4 represent necrotic cells permeable to the 7-AAD dye.  
 
With MIT treatment at the highest concentration tested, 75 µM, it appears that the 
profile was shifted to the right side with concomitant increase of cells in Q2, Q3 and 
Q4 indicating increased apoptotic and necrotic cells. This increased susceptibility to 
dye permeability is consistent with the response observed during cell cycle analysis 
using PI staining. 
 
Involvement of executer caspases (3 and 7) 
The activity of caspase 3/7 was assessed in SH-SY5Y cells treated with MIT. With 
incubation of MIT for either 4 or 18 hrs, at 100 µM and 300 µM MIT, there was 
significant activation of caspase 3/7 activity (Figure 6).  
 
ROS generation in SH-SY5Y cells treated with MIT 
An important mechanism whereby xenobiotics induce cell death is through the 
generation of reactive oxygen species (ROS). Intracellular ROS can be detected 
using the formation of the fluorescent product DCFH after hydrolysis of DCGH-DA. 
As shown in figure 7, the positive control, H202 generated a clear response in the SH-
SY5Y cell that was inhibited by pre-incubation (30 min prior to addition of H2O2) with 
NAC. Similar treatments with MIT failed to induce any detectable ROS response in 
this cell (Figure 7).  
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Effects of opioid receptor antagonists on treated SH-SY5Y cells 
We considered the possibility that the toxicity of MIT may be associated with 
interaction at the opiate receptor. The SH-SY5Y cells express predominantly the µ 
and δ opioid receptor 18. We therefore used a trypan blue assay to assess 
cytotoxicity effects of MIT in the presence of selective opioid receptor antagonists 
naloxone (µ and δ antagonist), naltrindole (δ antagonist) and cyprodime 
hydrobromide (µ antagonist). 
 
After 24 hr of treatment, naloxone at the concentration of 1 µM successfully inhibited 
cytotoxicity that is evident at 100 µM MIT (Figure 8). In contrast naltrindole failed to 
offer significant protection against MIT induced cytotoxicity and cyprodime 
hydrobromide was only partially protective (Figure 8). 
 
 
 
DISCUSSION 
 
The analgesic properties of Mitragyna speciosa plant have been described in vitro 
and in vivo, mainly using crude alkaloid extracts but also with its dominant alkaloid 
mitragynine (MIT) and congeners19, 20.  These medicinal properties have been 
reported for extracts of the leaves of this plant but not from other species of 
Mitragyna.  Several countries like Thailand, Myanmar, Malaysia and Australia have 
made possession of the plant illegal, due to its narcotic properties, yet preparations 
of the plant are available for sale over the internet.  The popularity of this herb in 
Western culture is increasing and some individuals are now taking it for self-
treatment of chronic pain and as an aid to opioid withdrawal4.  The potential toxicity of 
MIT and of other products derived from Mitragyna speciosa is currently poorly 
documented and recently there have been several reported fatalities associated with 
consumption of Kratom9-11.  The reason for these deaths is not understood but MIT 
toxicity is implicated. Therefore an in vitro toxicological assessment of its dominant 
alkaloid MIT was undertaken.  MIT was found to exert dose-dependent cytotoxic 
effects to human cell lines.  We demonstrated that MIT was toxic to all three cell lines 
Page 14 of 33Toxicology Research
 13 
examined and the human neuronal SH-SY5Y cell was chosen for further study as 
neuronal tissue is a high probability target for opiate-like compounds such as MIT. 
The concentration of MIT required to reduce the relative (to control) cell number by 
50% (IC50) following 24 hr treatment of SH-SY5Y cells was 7.5 x 10
-5 M. In contrast, 
we noted that low doses of MIT (3 x 10-7 M) stimulated cell proliferation during the 
first 48 h but this effect was lost at the 72 h time point. The reason for this stimulation 
of proliferation is not clear, especially since other classical opiate agonists, such as 
morphine, suppress rather than stimulate proliferation21.   
 
Many xenobiotics undergo metabolic activation in the process of exerting their 
cytotoxicity effects. CYP proteins are key enzymes involved in oxidative xenobiotic 
metabolism, therefore we examined if metabolism was involved in MIT cytotoxicity 
using MCL-5 cells (metabolically competent and express-CYP1A1, 1A2, 2A6, 2E1, 
3A4 and human epoxide hydrolase). We compared the toxicity of MIT in MCL-5 cells 
in the presence of inhibitors of the CYP enzymes.  Incubations in the presence of 
inhibitors of CYP3A4 and 1A1 failed to affect toxicity, but inhibitors of 2E1 and 2A6 
did protect against MIT toxicity, suggesting involvement of these enzymes.  
 
To further characterise the nature of the cytotoxicity of MIT, we examined SH-SY5Y 
cell cycle distribution, using flow cytometry16, 17.  SH-SY5Y cells treated with MIT 
appeared to be resistant to cell cycle effects except at the highest dose tested, 75 
µM, where there was evidence for a G1 arrest. An unexpected observation in these 
experiments was the right-shifting of the DNA profiles which was pronounced in the 
high dose of MIT. This phenomenon implies that the cells have taken up more PI, 
thus increasing the DNA staining intensity. The explanation for this phenomenon is 
unknown however, it could reflect plasma membrane integrity being compromised by 
the treatment, thus creating pores or increased membrane permeability.   
 
In view of the effect on cell cycle at 75 µM, we investigated the ability of MIT to 
damage DNA and induce mutation using the well-established L5178 tk+/- mouse 
lymphoma cell assay.  Under the conditions of the ICH agreed guidelines for this 
assay, MIT was not found to be genotoxic in the presence or absence of a metabolic 
activation system, although substantial toxicity was noted at the 75 µM concentration 
when RTG was lowered to 17%.   
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Since the cytotoxicity of MIT was accompanied by cell cycle arrest, it was proposed 
that these changes could be a result of alteration in the expression and activation of 
regulatory proteins such as p53.  In fact immunoblotting indicated the loss of the P53 
protein with MIT treatment. The mechanism of this loss is not obvious, but could 
involve compromised membrane integrity. Consistent with this, the right shift of the 
DNA profiles (increased PI staining) in the flow cytometry experiments indicates a 
mechanism in which the dyes could diffuse more easily into the cell. 
 
Further flow cytometry analysis using double staining with Annexin V conjugates and 
7-AAD supported this MIT-induced membrane permeability, with the dyes being more 
readily taken up by treated cells. These experiments further indicated that most of the 
treated cells were necrotic and late apoptotic populations.   
 
The ability of cysteine proteases, caspases 22, 23 to perform proteolytic cleavage at 
defined aspartate acid residues in various cellular substrates is an established 
marker of apoptosis24. We examined the involvement of executioner caspases 
(caspase 3 and 7) in MIT cytotoxicity in SH-SY5Y cells and found significant 
increases in caspases 3 and 7 activities at both concentrations of MIT tested. This 
finding suggests that the mode of the cell death of MIT treated cells involves caspase 
3 and 7 activation pathway and is indicative of apoptosis. 
 
Under normal circumstances, the low levels of ROS generated by mitochondria as a 
normal by-product of oxygen metabolism are usually removed by an abundance of 
endogenous free radical scavengers such as enzyme superoxide dismutases, 
glutathione and other cellular antioxidants such as ascorbic acid and vitamin E 25, 26. 
However xenobiotic insult, which causes mitochondrial malfunctions, may lead to 
generation of ROS in higher levels thus triggering oxidative stress, lipid peroxidation 
and finally cell death. In the present study, MIT treatment failed to induce ROS, 
suggesting this was not a mechanism of the apoptotic cell death noted here. 
 
MIT has been shown to exert its biological activities via opioid receptors mainly µ-, 
and δ- and to a lesser extent κ-opioid receptors 5, 27 28. The opioid analgesic, 
morphine is also known to exert its biological activities mainly via µ-opioid and also δ- 
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and κ-opioid receptors29  however the selective binding site of MIT for µ-receptor is 
reported to be of a different subtype from morphine5. Cell death induced by opioids is 
associated with their opioid receptor signalling, such as neuronal apoptosis induced 
by morphine due to opioid receptor desensitisation and uncoupling to pertussis toxin 
(PTX)-sensitive inhibitory G protein (Gi)30. Additionally, morphine has been shown to 
induce cell cycle block and apoptosis in MCF-7 and MDA-MB231 mammary cancer 
cells that was naloxone sensitive31; inhibited growth and proliferation and induced cell 
cycle arrest in MGC-803 gastric cells32; inhibited proliferation and increased 
apoptosis of neural progenitor cells that was reversed by naloxone, and the authors 
suggested the involvement of the µ opioid receptor33. Thus this information poses the 
question of whether the opioid receptors mediating the biological activity of the 
Mitragyna speciosa Korth plant may also mediate the MIT induced toxicity or cell 
death. Opiate receptor antagonists should therefore protect against MIT induced cell 
death. As anticipated, naloxone (µ- and δ-receptor antagonist) and cyprodime 
hydrobromide (µ- receptor antagonists) successfully gave protection against MIT 
toxicity. Interestingly the opiate agonist etorphine (exhibits activity through the µ, κ 
and δ opioid receptors) inhibited the cell growth of SK-N-SH cells, yet the inhibition 
was not prevented by naloxone, suggesting that the effects of etorphine might not be 
mediated by a classical opioid receptor34. These observations indicate that further 
work is required to define the mechanisms involved in the toxicity of MIT.    
 
Based on consumption of 20 leaves/day of Mitragyna speciosa, the estimated daily 
human exposure to MIT is about 17 mg for regular consumers3.  Assuming total body 
distribution of the drug (70 kg BW/person), in vivo concentrations are probably in 
order of 10-9 to 10-7 M MIT. Extrapolating cell based in vitro studies to whole animal 
studies require huge assumptions, but since the in vitro toxicity of MIT is not obvious 
until ≥ 75 µM, human consumption of Mitragyna speciosa Korth leaves at 
pharmacologically active doses would appear to be substantially lower than the 
threshold of toxicity predicted from this in vitro study. However, these assumptions do 
not take into account local concentrations of MIT in the GI tract after consumption, 
which could be significantly higher. The reported GI disturbance noted in Kratom 
addicts could reflect this potential toxicity and there have been several reports of 
fatalities associated with kratom consumption9-11. In these reports, the blood 
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concentrations of MIT ranged from 0.48 – 1.5 µM, which is fifty fold lower than the 
concentrations required to produce overt toxicity in the present in vitro toxicity study. 
Additionally, the study by McIntyre et al9 reported that liver concentrations of MIT 
(1.08 µM) were twice the blood levels. Although these reported fatalities were 
complicated  by the detection of other drug entities, MIT was implicated as 
contributing to the deaths. 
 
Conclusions 
Based on the current findings MIT has potential to cause cytotoxicity to mammalian 
cells. Since MIT is the dominant alkaloid found in Mitragyna speciosa Korth (Kratom), 
human addiction to Kratom is potentially harmful. The main target system of MIT 
pharmacology is the central nervous system and our studies with the human 
neuroblastoma cell line SH-SY5Y indicate that such cells are susceptible to MIT 
cytotoxicity, although MIT was found to exert dose dependant cytotoxicity effects in 
all human cell lines examined.  
 
The cytotoxicity events are initially seen as cell cycle arrest then proceed to cell 
death with increasing dose of MIT.  In addition, the metabolism studies also suggest 
that CYP 2E1 and possibly 2A6 activity appeared to be involved in MIT cytotoxicity. 
From the human perspective, if Mitragyna speciosa leaves were to be ingested by 
individuals with elevated CYP 2E1 activity such as high consumers of alcohol, the 
toxicity of Mitragyna speciosa leaves and extracts could be potentiated. This is 
potentially of significance since the local concentration of MIT in the GI tract after 
consumption of Mitragyna speciosa is likely to be higher than systemic exposure; an 
additional susceptibility factor is that the GI tract is known to express CYP2E1. This 
is consistent with the GI disturbance noted amongst Kratom addicts. Of particular 
importance is the reported fatalities associated with kratom consumption, where the 
blood concentrations of MIT were in the µM range. This is significantly lower than the 
levels of MIT required to induce toxicity we report here in our in vitro mechanistic 
studies and clearly the potential for MIT to cause toxicity in vivo warrants further 
investigation. 
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FIGURES  
 
Figure 1 The structure of Mitragynine 
 
Figure 2 Cytotoxicity of MIT treated cells. 
A. Proliferation of HEK 293 cells with MIT treatment.  
B. Proliferation of SH-SY5Y cells with MIT treatment.  
C. Proliferation of MCL-5 cells treated with MIT and DED (100 µM) or ATZ (25 
µM) for 48 hr.  
D. Clonogenicity of SH-SY5Y cells after MIT treatment for 24 h. 
Cell number was assessed using Trypan blue exclusion and clonogenicity by 
counting colonies. Values are the mean ± SEM of three or four independent cultures.  
*P<0.05 vs respective MIT alone controls , ANOVA with Tukey-Kramer post test. 
 
Figure 3 Effects of MIT on the cell cycle distribution of SH-SY5Y cells. 
Cells were treated for 24 h with MIT. Representative histograms are shown and 
values of each phase of the cell cycle are the mean of the three independent 
experiments. 
 
Figure 4  P53 expression in SH-SY5Y cells treated with MIT for 24 h.  
A representative immunoblot is shown. For quantitation, bars are normalised to the β-
actin controls and are the mean of three independent experiments with SEM.   
 
Figure 5 Flow cytometry assessment of apoptosis and necrosis of SH-SY5Y cells 
after 24 hr treatment with MIT. 
Treated cells were stained with Alexa Fluor® 647-Annexin V conjugate and 7-AAD.  
Four quadrants (Q) representing normal cells (Q1), early apoptosis cells (Q2), late 
apoptotic/necrotic cells (Q3) and necrotic cells (Q4).  
Table shows mean ± SEM values of % cells in each quadrant from 3 independent 
cultures ** Significantly different from respective control, P<0.01, ANOVA with 
Dunnet post test. 
 
Figure 6 Activity of executor caspases 3/7 in SH-SY5Y cells treated with MIT for 4 hr 
or 18 hr incubation. 
Values are mean ± SEM for 3 independent cultures. Significantly different from 
respective control, **P<0.01, ANOVA with Dunnet post test. 
 
Figure 7 Measurement of ROS with DCFH-DA in SH-SY5Y cells treated with H202, 
or MIT with or without NAC.   
Fluorescent readings are normalised to the respective control group. Values are 
mean ± SEM for 3 independent cultures.  
 
Figure 8 Trypan blue exclusion assay of SH-SY5Y cells after 24 hr treatment with A) 
MIT ± Naloxone (N), B) MIT ± Naltrindole (Nalt), C) MIT ± Cyprodime hydrobromide 
(C).  
Values are mean ± SEM for 3 independent cultures. Significantly different from 
respective control, * P<0.05, ANOVA with Bonferroni post test. 
 
 
Page 22 of 33Toxicology Research
 21 
Table 1.  Effect of MIT on cell growth. 
 
_________________________________________________ 
                                                                      IC50                           
   _________________________________ 
 
Cell line               MIT  (µMolar)______ 
 
SH-SY5Y            75 
 
HEK 293            240 
 
MCL-5             80 
______________________________________________________  
 
IC50 values are the concentration required to reduce the relative (to control) cell 
number by 50% after 24 hr treatment with MIT.  The values were interpolated from 
cell survival curves. 
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Table 2.  Genetic toxicology of MIT in L5178 tk+/- mouse lymphoma cells 
 
Substance Concentration (µM) RTG
a Mutantsb 
tk-/- (MF) 
3 h incubation +S9    
MIT 0 100 77 
12.5 99 72 
25l 91 71 
50 96 106 
75 92 101 
DMBA  
(positive control) 
1 µg/ml 78 550 
    
24 h incubation (no S9)    
MIT 0 100 88 
12.5 74 56 
25 81 104 
50 37 167 
75 17 114 
MMS 
(Positive control) 
5 µg/ml 87 590 
 
a  RTG Relative total growth (%) – measure of cell growth relative to control. 
b  MF mutant frequency (tk-/- mutants per 106 clone forming cells) 
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The cytotoxicity of mitragynine, the dominant alkaloid of the narcotic-like 
herb, Mitragyna speciosa Korth (Kratom) involves cell cycle arrest, 
apoptosis and opiate receptors.  
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G1: 99.07% 
S: 0.75% 
G2/M: 0.187% 
  
                  
Vehicle–treated control 0.3 mM MIT 
30 mM MIT 
15 mM MIT 3 mM MIT 
75 mM MIT 
MIT for 24 h 
G1: 67.2% 
S: 24.2% 
G2/M: 8.6% 
G1: 65.8% 
S: 26.0% 
G2/M: 8.2% 
G1: 65.6% 
S: 27.8% 
G2/M: 6.6% 
G1: 62% 
S: 30.7% 
G2/M: 7.3% 
G1: 63.5 % 
S: 30.6% 
G2/M: 5.92% 
Figure 3 
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MIT (µM) Q1 (%) Q2 (%) Q3 (%) Q4 (%) 
Control 91.3 ±1.25 1.95 ±0.23 5.36 ±0.94 1.4 ± 0.56 
0.3 91.9 ± 0.6 1.8 ± 0.13 5.09 ± 0.36 1.21 ± 0.27 
3 90.8 ± 0.43 1.97 ± 0.3 5.92 ± 0.33 1.26 ± 0.18 
15 92.2 ± 0.47 1.57 ± 0.09 4.97 ± 0.3 1.27 ± 0.34 
30 89.9 ± 1.1 1.37 ± 0.04 5.94 ± 0.63 2.84 ± 0.5 
75 78.4 ± 1.42** 2.3 ± 0.65 9.3 ± 0.5** 9.9 ± 0.95** 
Q1 
Q2 Q3 
Q4 
control 0.3mM 3mM 
15mM 30mM 75mM 
Figure 5 
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